Analytical Data
-
Gene name
PRA1
- Application
-
Alternative Names
PRA1；PRA1；PRAF1；Prenylated Rab acceptor Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UI14
-
Expression Region
1-185aa
-
AA Sequence
MAAQKDQQKDAEAEGLSGTTLLPKLIPSGAGREWLERRRATIRPWSTFVDQQRFSRPRNLGELCQRLVRNVEYYQSNYVFVFLGLILYCVVTSPMLLVALAVFFGACYILYLRTLESKLVLFGREVSPAHQYALAGGISFPFFWLAGAGSAVFWVLGATLVVIGSHAAFHQIEAVDGEELQMEPV
-
Molecular Weight
20.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PRA1 (Protein Regulator of Antigen Presentation) is a pivotal protein involved in the immune response, particularly in the presentation of antigens by Major Histocompatibility Complex (MHC) Class I molecules. This protein is known to play a critical role in the stabilization and maturation of MHC Class I, which is essential for the effective display of peptide fragments from intracellular proteins to CD8+ T cells. Understanding PRA1 and its functions can unveil significant insights into immune system regulation and potential therapeutic targets for autoimmune diseases, viral infections, and cancer immunotherapy. Research has shown that alterations in PRA1 function can lead to impaired antigen presentation, consequently affecting T cell activation and overall immune responses. As a result, recombinant PRA1 protein has become a focal point for studies aiming to elucidate its structure-function relationships, regulatory mechanisms, and interactions with other cellular components in antigen processing pathways. Moreover, the development of recombinant PRA1 proteins could facilitate the generation of novel vaccines and immunotherapeutics, enhancing the efficacy of treatments designed to harness or modulate the immune system. Thus, the exploration of PRA1 and its recombinant forms holds promise for advancing our understanding of immunology and for the development of innovative strategies in disease management.
